Bacopin®: A Comprehensive Encyclopedic Reference
1. Identity and Botanical Description
1.1 Trade Name and Proprietary Status
Bacopin® is a registered trademark belonging to Sabinsa Corporation, a manufacturer and supplier of standardized herbal extracts. Bacopin® is an extract prepared from the dried stems and leaves of Bacopa monnieri, standardized to contain bacosides — the key active compounds associated with its beneficial effects — and is available in different strengths standardized to 20%, 40%, and 50% bacosides. The trademark has been registered since at least the late 1990s. Bacopin® is commonly referred to as Brahmi and is a powdered extract of the plant Bacopa monniera standardized to contain a minimum of 20% total bacosides A & B.
1.2 Botanical Identity and Source Plant
Bacopa monnieri (L.) Wettst. belongs to the family Plantaginaceae and is a perennial plant that grows in wet, marshy areas, characterized by its small, oblong leaves and pale blue or white flowers. It is commonly known by several names, including Brahmi, water hyssop, and herb of grace. Known as water hyssop and commonly called "Brahmi," it is a small, creeping, succulent herb from the Plantaginaceae family, popularly employed in Ayurvedic medicine as a nerve tonic to improve memory and cognition.
The plant is a perennial, creeping, somewhat fleshy herb found throughout India in marshy grounds and in other Asian countries, Australia, Europe, Africa, and North and South America. It has been noted in taxonomic literature that its earlier classification placed it in the family Scrophulariaceae, but modern classification assigns it to Plantaginaceae.
1.3 Common Names and Synonyms
- Scientific names: Bacopa monnieri (L.) Wettst.; Bacopa monniera (L.) Wettst. (alternate spelling used in older literature); Herpestis monniera (older synonym)
- Common names: Brahmi (India), Brahmi (Ayurvedic), Waterhyssop, Herb of Grace, Indian Pennywort
- Trade/proprietary extract names: Bacopin® (Sabinsa Corporation); BaCognize® (Verdure Sciences); CDRI 08 / KeenMind (Central Drug Research Institute, India)
1.4 Common Forms and Preparations
Bacopin® and related standardized Bacopa extracts are commercially available in multiple dosage forms. Bacopin® is available as a dietary supplement and can be found in a variety of forms, including capsules, tablets, and liquid extracts. In traditional Ayurvedic practice, preparations have historically differed considerably from modern standardized extracts. The dried herb can be infused in hot water for a cup of bacopa tea; powders or extracts can also be used in beverages or, as in East Indian tradition, prepared in ghee, warm milk, or honey. Another traditional form is medicated oil applied topically, typically achieved by infusing the dried herb in sesame oil for several weeks.
In classical Ayurvedic medicine, Bacopa was incorporated into named compound formulations. Bacopa monnieri-based formulations such as Brahmi ghrita, Brahmi rasayana, Brahmi vati, and Saraswata ghrita are widely used in Ayurvedic medicine.
Most parts of the plant have been used traditionally, but modern preparations include extracts of the stem and leaves. Bacopa monnieri is fat soluble and requires a lipid transporter to be absorbed, so it should be supplemented alongside a meal.
2. Traditional and Historical Use
2.1 Ayurvedic Medicine — India
References to Bacopa monnieri date back over 3,000 years in classical Ayurvedic texts like the Charaka Samhita and Sushruta Samhita, where Brahmi was praised as a medhya rasayana — a rejuvenator for intellect and mental clarity. The concept of medhya rasayana in Ayurveda refers to a class of herbs used specifically to sharpen intelligence and support mental function.
Brahmi has been applied in Ayurveda since many generations as a nerve tonic and treatment of neurological disease, and in the 16th century it is recommended in Ayurvedic texts including the Caraka Samhita for the treatment of a wide range of mental illnesses. Bacopa monnieri was described around the 6th century AD in various old textbooks including the Charaka Samhita, Atharvaveda, and Sushruta Samhita under the medhaya rasayan — a class of herbs used to sharpen intelligence and fight against mental disorders.
Indian scholars and yogis were said to use Bacopa before intense study or deep meditation to strengthen their mental clarity and spiritual focus. Ancient practitioners in Vedic times recommended Brahmi for students preparing for exams, scholars reciting long verses, and monks engaged in deep meditation.
Bacopa monnieri (often called brahmi) is a botanical frequently used in Ayurvedic medicine. The main indications for using Bacopa in Ayurvedic medicine are memory improvement, insomnia, epilepsy, and as an anxiolytic. Since at least the sixth century A.D., bacopa has been used in Ayurvedic medicine as a diuretic and tonic for the nervous system as well as the heart.
Traditional preparations in Ayurveda went beyond simple leaf decoctions. In Kerala's traditional Ayurveda, Brahmi leaves are crushed into a paste for topical relief of ulcers and minor wounds, while decoctions or ghrita (ghee-based formulations) target nervous exhaustion and anxiety. The Charaka Samhita describes Brahmi ghrita — a medicated clarified butter preparation — for cognitive enhancement and medhya (intellect-promoting) purposes.
Traditional daily doses in Ayurvedic practice have been documented separately from modern standardized extract doses. The daily doses generally recommended in traditional practice are 8–16 ml of the infusion or 5–10 g of the powder.
2.2 Other Traditional Systems
Across Southeast Asia and in traditional Unani medicine of Persia, Bacopa monnieri was similarly valued for boosting memory and alleviating mental fatigue. The plant's geographic range and traditional application thus extended beyond the Indian subcontinent across much of Asia.
Historical clinical use from early research also documented specific applications. A clinical trial of 35 patients with diagnosed anxiety neurosis demonstrated that administration of Brahmi syrup (equivalent to 12 g dry crude extract of Bacopa) resulted in a significant decrease in anxiety symptoms, level of anxiety, level of disability, and mental fatigue, and exhibited considerable increase in immediate memory span (Singh, R.H. et al., Journal of Research in Ayurveda and Sidda, 1980).
3. Phytochemistry: Key Constituents and Active Compounds
3.1 Overview of Secondary Metabolites
Phytochemical studies over the last eight decades resulted in the isolation of 98 secondary metabolites from B. monnieri, including: dammarane-type triterpenoid saponins (34), pentacyclic triterpenes (6), phenylethyl glycosides (12), phenylpropanoid glycosides (2), cucurbitacins (7), steroids (8), flavonoids (6), alkaloids (3), and other miscellaneous compounds (20).
Bacopa monnieri is rich in secondary metabolites, including a number of alkaloids (herpestine, brahmine), saponins (bacosides, betulic acid, and hersaponin), alcohols, flavonoids, sterol glycosides, sugars, amino acids, and cucurbitacins.
3.2 Bacosides: The Primary Active Compounds
The bacosides are the most pharmacologically significant class of compounds in Bacopa and the primary target of standardization in all commercial extracts including Bacopin®. The principal constituents of B. monniera are triterpene saponins of the dammarane class, named bacosides and bacopasaponins. There are two types of saponins — jujubogenin and pseudojujubogenin — which differ only in the nature of the sugar units in the glycosidic chain and the position of the olefinic side chain in the aglycone.
Bacopa monnieri contains a family of saponins called bacosides — primarily bacoside A and bacoside B, along with their glycoside sub-fractions (bacoside A3, bacopasaponin C, and bacopacide I through III). Bacopa monnieri contains active compounds including bacosides A and B, betulinic acid, loliolide, asiatic acid, and quercetin.
The bioactive phyto-constituents like the dammarane-type triterpenoid saponins — bacosides A, B, and C — were reported mostly for neuroprotective, nootropic, and memory-enhancing properties. The triterpenoid saponins are believed to be responsible for most of the herb's pharmacological actions.
3.3 Alkaloids and Other Bioactives
Series of biochemical studies identified different pharmacological compounds from ethanolic extracts of Bacopa, which include alkaloids (brahmine, nicotine, and herpestine), saponins (monnierin, hersaponin), sterols (β-sitosterol, stigmasterol), d-mannitol, and betulinic acid.
3.4 Standardization in Bacopin® vs. Other Extracts
The standardization level is a critical variable that differentiates commercial bacopa products. Bacopin® is standardized to contain bacosides — the key active compounds associated with its beneficial effects — and is available in different strengths standardized to 20%, 40%, and 50% bacosides. Bacopin® is Sabinsa's branded Bacopa monnieri extract standardized to ≥20% bacosides by gravimetry.
The critical pharmacological point is that raw dried herb and a standardized extract are not interchangeable. A crude leaf powder might contain anywhere from 2% to 8% total bacosides by weight. Most clinical trials used extracts standardized to 55% bacosides (the KeenMind/CDRI 08 extract) or 20% bacosides (a separate proprietary preparation). Sabinsa's standardization differs from competing brands such as BaCognize and CDRI 08, with Bacopin using a different extraction profile and bacoside specification.
4. Mechanisms of Action
4.1 Overview of Proposed Mechanisms
Multiple mechanisms have been identified through preclinical and, to a lesser extent, clinical research. Current evidence suggests Bacopa monnieri acts via the following mechanisms: anti-oxidant neuroprotection (via redox and enzyme induction), acetylcholinesterase inhibition and/or choline acetyltransferase activation, β-amyloid reduction, increased cerebral blood flow, and neurotransmitter modulation of acetylcholine (ACh), 5-hydroxytryptamine (5-HT), and dopamine (DA).
4.2 Antioxidant and Neuroprotective Actions
Bacopa monnieri amplifies free radical scavenging mechanisms and preserves cells in the hippocampus, prefrontal cortex, and striatum, protecting them against cytotoxicity. Furthermore, it decreases lipoxygenase activity, decreases lipid peroxidation, increases glutathione peroxidase (GPX) activity, and promotes iron chelation. Based on animal studies, the bacosides appear to have antioxidant activity in areas of the brain including the hippocampus, frontal cortex, and striatum. Bacopa enhances certain enzymes including superoxide dismutase (SOD) and catalase involved in generation and scavenging of reactive oxygen species (ROS) in the brain, possibly by NRF2 activation.
4.3 Cholinergic Modulation
Bacopa monnieri may inhibit the acetylcholinesterase enzyme, which may increase acetylcholine levels. As a result, Bacopa could counteract the effects of anticholinergic drugs and may worsen bradycardia and exacerbate conditions such as gastrointestinal obstruction, peptic ulcer disease, pulmonary conditions such as asthma and COPD, or urogenital tract obstruction.
4.4 Serotonergic and Dopaminergic Modulation
Bacopa primarily either acts via antioxidant mechanism (neuroprotection) or alters different neurotransmitters — serotonin (5-HT), dopamine (DA), acetylcholine (ACh), and γ-aminobutyric acid (GABA) — to execute its pharmacological effect. Among them, 5-HT has been shown to fine-tune neural plasticity, which is a substrate for memory formation. Bacosides increase memory function through the enzyme Tryptophan Hydroxylase (TPH2) and increase the serotonin transporter (SERT).
4.5 Synaptic and Neuronal Structural Effects
The dammarane-type triterpenoid saponin and the aglycone unit in triterpenoid saponins (jujubogenin or pseudojujubogenin) in bacosides can repair damaged neurons, stimulate kinase activity, restore synaptic function, and improve nerve transmission. Metabolites or active compounds from Bacopa monnieri interact with the dopamine and serotonergic systems, but the main molecular mechanism concerns promoting neuron communication — achieved by increasing the growth of nerve endings, also called dendrites.
4.6 β-Amyloid Reduction and Neurodegeneration Relevance
By boosting antioxidant defense mechanisms, lowering oxidative stress, and altering neurotransmitter levels, Bacopa monnieri demonstrates neuroprotective effects. By blocking the activity of acetylcholinesterase, lowering the production of β-amyloid plaques, and modifying neurotransmitter levels, it has demonstrated potential for treating neurodegenerative disorders such as Alzheimer's and Parkinson's disease. These findings are predominantly from animal and in vitro work, not established clinical evidence.
4.7 Stress Response Pathway
Data indicate that Bacopa monnieri has potential to modulate the activities of Hsp70, cytochrome P450, and SOD, thereby possibly allowing the brain to be prepared to act under adverse conditions such as stress. This stress-buffering activity underlies its classification in some literature as an adaptogen.
5. Scientific Evidence by Area of Use
5.1 Memory and General Cognitive Function
Systematic Reviews and Meta-Analyses
The strongest body of research on Bacopa extracts (including the 20% bacoside standardization level used in Bacopin®) concerns memory and general cognition.
A systematic review of randomized controlled trials (Pase et al., 2012, published in the Journal of Alternative and Complementary Medicine) involved a systematic search of multiple databases, assessed trials for methodological quality, focused on adult humans without dementia or significant cognitive impairment, and examined Bacopa extracts administered over long-term supplementation periods. Six studies met the final inclusion criteria. Trials were all conducted over 12 weeks, with three different Bacopa extracts used at dosages of 300–450 mg extract per day.
Across studies, Bacopa improved performance on 9 of 17 tests in the domain of memory free recall. The review's conclusions were: there is some evidence to suggest that Bacopa improves memory free recall, with evidence for enhancement in other cognitive abilities currently lacking, perhaps due to inconsistent measures employed by studies across these cognitive domains. Research into the nootropic effects of Bacopa is in its infancy, with research still yet to investigate the effects of Bacopa across all human cognitive abilities. Future research should examine the nootropic effects of Bacopa at varied dosages and across different extracts.
A separate formal meta-analysis of randomized controlled trials concluded that the systematic review and meta-analysis examined the beneficial effects of Bacopa monnieri extract on cognitive function, with findings demonstrating that Bacopa monnieri extract has the potential to improve cognitive performance, particularly speed of attention by reducing choice reaction time.
Many clinical studies have demonstrated improvements in verbal learning, delayed word recall, memory acquisition, and anxiety reduction with using Bacopa. It has been described as a calming cognitive enhancer.
Bacopa monnieri is used in Ayurvedic traditional medicine in the belief it may improve memory and various ailments. There is no good evidence that it improves cognitive performance and memory, while its safety and effectiveness remain uncertain. This assessment from Wikipedia, citing systematic evidence, reflects the ongoing debate about the strength of the human clinical evidence.
Key Individual Clinical Trials
A small (17-patient) randomized controlled trial published in 2014 demonstrated statistically significant improvement in cognitive performance (mental arithmetic, Stroop, letter search, and visual tracking), improved mood, and a decreased cortisol response from stress after a single dose of Bacopa at 320 mg and 640 mg.
In a clinical study by Benso et al., doses of 320 mg and 640 mg were shown to have a positive effect on human cognitive function (memorization, eye tracking, etc.), with slightly stronger effects observed in those who received the 640 mg dose.
Some modest improvements in memory performance and benefits in conditions like Alzheimer's and depression were observed, but the results were inconsistent across tests, indicating the need for more robust, standardized clinical studies.
Evidence Strength Assessment
The overall evidence base for cognitive and memory effects is preliminary to moderately supportive. Signal for memory free recall is the most consistent finding across trials, but trials are generally small, and the heterogeneity in extract types, standardizations, and cognitive tests used limits definitive conclusions.
5.2 Anxiety and Stress
Both animal and clinical research data support the traditional Indian Ayurvedic use of Bacopa monnieri for stress and anxiety. Bacopa monnieri may reduce stress, anxiety, and depression symptoms in part related to its effects on modulating cortisol, a chemical released by the stress system.
A 2008 randomized, double-blind, placebo-controlled trial (Calabrese et al., 2008, PMCID: PMC3153866) examined the effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly. This trial is considered part of the foundational evidence base.
Twenty-two included clinical trials demonstrated that BM can reduce Nuclear Factor-κB phosphorylation, improve emotional function, cognitive functions, anhedonia, hyperactivity, sleep routine, depression, attention deficit, learning problems, memory retention, impulsivity, and psychiatric problems. This finding comes from a 2024 systematic review (PMC11047749) focused on neuroprotection, inflammation, and oxidative stress.
Evidence strength for anxiety and stress: preliminary to moderate. Animal models and small human trials show anxiolytic signal. Larger, well-powered trials are needed.
5.3 Attention-Deficit / Hyperactivity Disorder (ADHD)
Bacopa monnieri has been studied for its potential in treating ADHD, among other conditions. The effects of Bacopa monnieri were tested in children with ADHD, and the outcomes showed that there was a reduction of ADHD symptoms, attention deficit, learning problems, impulsivity, and psychiatric problems. However, the sample sizes in these studies are a limiting factor.
In a study conducted by Dave et al., a safe dose for children aged 6 to 12 years was developed. The study involved 31 children with ADHD who were given a dose of 225 mg per day for 6 months. The dosage proved not only safe but also effective in eliminating ADHD symptoms in children within that age range.
CDRI 08 is a special extract of Bacopa monnieri which has been subjected to hundreds of scientific studies and shown in human randomized controlled trials to improve memory, attention, and mood. It was hypothesized that chronic administration of CDRI 08 would improve attention, concentration, and behaviour in children with high levels of hyperactivity and/or inattention.
Evidence strength for ADHD: preliminary and limited. The trials available are generally small and methodologically inconsistent; larger, placebo-controlled trials are required before firm conclusions can be drawn.
5.4 Alzheimer's Disease and Neurodegenerative Conditions
Bacopa monnieri has shown neuroprotective effects in animal and in vitro studies; human studies on patients with Alzheimer disease have been inconclusive. A systematic review (Basheer et al., 2022, PMCID: PMC9379783) searched PubMed, EMBASE, Cochrane Library, and clinical trial registries. The comprehensive search yielded 5 eligible studies. Three studies used Bacopa monnieri in combination with herbal extracts while the remaining 2 used Bacopa monnieri extracts only. Two studies compared Bacopa monnieri with donepezil while others used a placebo as the control.
There is evidence for potential attenuation of dementia, Parkinson's disease, and epilepsy. However, these findings are predominantly preclinical. Evidence strength for Alzheimer's disease and neurodegeneration: animal/in vitro and preliminary clinical. No high-quality, large-scale RCTs in Alzheimer's patients exist as of the available literature; results from existing human studies are inconsistent.
5.5 Pharmacological Activities Beyond Neurology
Pharmacological activities of Bacopa monnieri include anti-epileptic, anticancer, anti-ulcer, and anti-inflammatory actions. The plant also possesses antimicrobial, antioxidant, anti-inflammatory, and gastroprotective properties. These additional pharmacological profiles are, however, based predominantly on preclinical (animal and in vitro) data, and human clinical evidence in these areas is sparse or absent.
Other animal and human clinical studies support the beneficial actions of Bacopa monnieri on other indications as well, such as epilepsy, bronchitis, asthma, gastrointestinal disorders, and hypothyroidism.
6. Body Systems Associated with Bacopa monnieri / Bacopin®
- Central Nervous System: Bacopa monnieri is a well-known nootropic herb, commonly used in the traditional system of Ayurveda for improving memory and reducing anxiety, and is mainly known as a neuronal booster and cognitive enhancer.
- Neurotransmitter Systems: Diverse mechanisms of action for its cognitive effects have been proposed, including acetylcholinesterase (AChE) inhibition, antioxidant neuroprotection, β-amyloid reduction, neurotransmitter modulation (acetylcholine, 5-HT, dopamine), choline acetyltransferase activation, and increased cerebral blood flow.
- Endocrine / Thyroid: Animal research suggests Bacopa may increase thyroxine levels (T4) in mice by about 40%.
- Gastrointestinal System: Bacopa has documented effects on gut motility, both as a traditional remedy for digestive complaints and as a source of adverse gastrointestinal effects at supplemental doses.
- Cardiovascular System: Traditional Ayurvedic use included the cardiovascular system. Preclinical data also suggests effects on cerebral blood flow.
7. Dosage Forms and Reported Clinical Dosages
The most common dose for Bacopa monnieri is 300 mg per day, assuming that the total bacoside content is approximately 55% of the extract by weight. Doses of up to 600 mg per day have been used in some studies. A phase I study found doses of 300 mg and 450 mg per day to be safe in healthy adults.
Across trials included in the 2012 systematic review (Pase et al.), three different Bacopa extracts were used at dosages of 300–450 mg extract per day.
Clinical studies have demonstrated that daily doses of 300 to 600 mg of Bacopa monnieri extract standardized for the amount of bacosides — equivalent to 5 to 10 g of the dried herb — can enhance cognitive function and alleviate symptoms of anxiety and depression.
A small randomized controlled trial demonstrated statistically significant improvement in cognitive performance and a decreased cortisol response from stress after 1 dose of Bacopa at 320 mg and 640 mg.
A pediatric study involved 31 children with ADHD who were given a dose of 225 mg per day for 6 months.
For Bacopin® specifically: the studied dose is 100–300 mg/day Bacopin standardized extract, typically split into 1–2 daily doses with food. Some sources cite a daily dose of 120 mg of Bacopa monnieri standardized to 20% bacosides as a common starting point for Bacopin®.
Effects typically develop slowly over 8–12 weeks rather than acutely.
Clinical studies have equivalenced 300–600 mg of standardized extract to 5–10 g of the dried herb per day.
8. Safety Considerations and Drug Interactions
8.1 General Safety Profile
Concerning safety, Bacopa monnieri has been found to be generally non-toxic, with no serious side effects reported. However, interactions with certain medications and contraindications in conditions like hyperthyroidism should be considered.
Bacopa has a high therapeutic index and is generally well-tolerated. The most common side effects are gastrointestinal, including increased stool frequency, nausea, and abdominal cramps.
BM appears to exhibit low toxicity in model organisms and humans; however, long-term studies of toxicity in humans have yet to be conducted. The long-term effect of BM on humans is unknown, but animal models suggest considerable protection against age-related neurodegeneration rather than progressive toxicity or tolerance formation.
8.2 Gastrointestinal Adverse Effects
The most commonly reported adverse effects of B. monnieri in humans are nausea, increased intestinal motility, and gastrointestinal upset. Side effects associated with Bacopa monnieri are generally mild, and gastrointestinal complaints are reported most often.
8.3 Thyroid Interaction
Animal research suggests Bacopa may increase thyroxine levels (T4) in mice by about 40%. T4 concentration was increased with the use of Bacopa extract. Consuming Bacopa concomitantly with thyroid hormone may result in too much thyroid hormone and increase the potential for adverse effects. This is one of the more clinically significant documented interactions. Contraindications in conditions like hyperthyroidism should be considered.
8.4 Cytochrome P450 Enzyme Inhibition
Bacopa has been shown to inhibit human cytochrome P450 enzymes, which could contribute to herb-drug interactions when co-administered orally with medications metabolized by CYP1A2, CYP2C9, CYP3A4, and CYP2C19. An in vitro study found that Bacopa monnieri inhibited the activity of certain cytochrome P450 enzymes (e.g., CYP3A4, CYP2C9, CYP2C19) and could therefore cause significant adverse reactions when taken alongside drugs that are metabolized by these enzymes, like clozapine, haloperidol, fluoxetine, and phenytoin.
8.5 Cholinergic Drug Interactions
Bacopa monnieri may inhibit the acetylcholinesterase enzyme, which may increase acetylcholine levels. As a result, Bacopa could counteract the effects of anticholinergic drugs and may worsen bradycardia and exacerbate conditions such as gastrointestinal obstruction, peptic ulcer disease, pulmonary conditions such as asthma and COPD, or urogenital tract obstruction.
In a case study, a patient taking cevimeline (a cholinergic agonist that is metabolized by P450 enzymes) experienced malaise, nausea, and tachycardia after taking a supplement containing Bacopa monnieri. The clinicians suspected cholinergic toxicity due to the herb-drug interaction. Symptoms resolved once the supplement was discontinued.
Because Bacopa also raises acetylcholine levels, combining it with medications that do the same thing (commonly prescribed for Alzheimer's disease) could push acetylcholine too high.
8.6 Cardiovascular Considerations
Due to its function, high acetylcholine levels may lead to bradycardia, so individuals predisposed to slow heart rates should use caution regarding Bacopa monnieri extract supplementation.
8.7 Galantamine Interaction
Early studies suggest that the concomitant use of Bacopa monnieri and galantamine (an acetylcholinesterase inhibitor used for Alzheimer's disease) may have a synergistic effect on cognitive function. However, there is a need for further research into the potential risk of side effects and pharmacodynamic interactions.
8.8 Pregnancy, Lactation, and Vulnerable Populations
Further research is needed to determine optimal dosages and ensure safety, especially for pregnant and breastfeeding women. Further research is needed to determine optimal dosages and ensure safety, especially for pregnant and breastfeeding women.
8.9 Regulatory Standing
In 2019, the FDA issued warning letters to manufacturers of dietary supplements containing B. monnieri that advertised health claims for treating or preventing stomach disease, Alzheimer's disease, hypoglycemia, blood pressure, and anxiety, stating these were unproven and illegal. The FDA stated that no B. monnieri products have been approved for medical purposes.
According to the 2026 WADA List of Prohibited Substances, Bacopa monnieri is not prohibited.
9. Evidence Limitations and Research Gaps
Studies on the activity of plant raw materials are particularly challenging due to the various types of extracts, which differ in composition and concentration of active compounds. The complexity of plant matrices and the diversity of extraction methods further complicate the standardization and reproducibility of results.
There is limited research that specifically evaluates drug interactions with Bacopa monnieri. The evidence base specifically for the Bacopin® trademarked extract is narrower than for the CDRI 08 or BaCognize® extracts, both of which have more branded clinical trial data. The published Bacopa class evidence is moderately positive for memory and learning at 300–450 mg/day, though Bacopin-specific RCTs are fewer than BaCognize-specific trials.
There is some evidence to suggest that Bacopa improves memory free recall, with evidence for enhancement in other cognitive abilities currently lacking, perhaps due to inconsistent measures employed by studies across these cognitive domains. Research into the nootropic effects of Bacopa is in its infancy, with research still yet to investigate the effects of Bacopa across all human cognitive abilities.
References
- Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability — PMC 2025
- Pase MP et al. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials. J Altern Complement Med. 2012 — PubMed
- DARE Quality-assessed Review: The cognitive-enhancing effects of Bacopa monnieri — NCBI Bookshelf
- Bacopa monnieri — StatPearls — NCBI Bookshelf
- Aguiar S, Borowski T. Neuropharmacological Review of the Nootropic Herb Bacopa monnieri — PMC 2013
- Molecular and Functional Characterization of Bacopa monniera: A Retrospective Review — PMC 2015
- Investigating the Neuroprotective and Cognitive-Enhancing Effects of Bacopa monnieri: A Systematic Review Focused on Inflammation, Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis — PMC 2024
- Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials — PMC 2022
- Bacopa monnieri and Their Bioactive Compounds Inferred Multi-Target Treatment Strategy for Neurological Diseases: A Cheminformatics and System Pharmacology Approach — PMC 2020
- Bacopa monnieri: A promising herbal approach for neurodegenerative disease treatment supported by in silico and in vitro research — PMC 2023
- Systematic Overview of Bacopa monnieri (L.) Wettst. Dominant Poly-Herbal Formulas in Children and Adolescents — PMC 2018
- Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials — Interactive Journal of Medical Research 2022
- Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract — ScienceDirect 2014
- Bacopa monnieri — Overview — ScienceDirect Topics (Pharmacology)
- Bacopa monnieri — Overview — ScienceDirect Topics (Agricultural and Biological Sciences)
- Bacopa monnieri, a wonder plant in the backyard: Emphasizing the role of the microbiome — ScienceDirect 2025
- Bacopa monnieri: Benefits, Dosage, and Side Effects — Examine.com
- Could Bacopa monnieri interact with medications? — Examine.com
- Bacopa monnieri — Wikipedia
- A Randomized Controlled Trial Investigating the Effects of a Special Extract of Bacopa monnieri (CDRI 08) on Hyperactivity and Inattention in Male Children and Adolescents: BACHI Study Protocol — PubMed 2015
- Biotechnology for propagation and secondary metabolite production in Bacopa monnieri — PubMed 2022
- Bacopa monnieri (Brahmi): Phytochemistry and Use in Traditional Ayurvedic Formulations — ResearchGate 2022
- A bacosides containing Bacopa monnieri extract alleviates allodynia and hyperalgesia in the chronic constriction injury model of neuropathic pain — PMC 2017
- Sabinsa Corporation Granted Registered Trademark of Bacopin® — Sabinsa Official Site
- Sabinsa Corporation Granted Registered Trademark of Bacopin® — Sami-Sabinsa Group Press Release
- Bacopin® by Sabinsa Corporation — NXT Ingredients
- Bacopin® — Official Sabinsa Product Page
- Bacopa monnieri (L.) Wettst. (Plantaginaceae) — Springer Handbook of Medicinal Plants
- Phytochemical and Pharmacological Profile of Bacopa monnieri — International Journal of Pharmaceutical Sciences and Research
- Bacopa monnieri Extract As a Neuroprotective and Cognitive Enhancement Agent — Scilight 2023
- Bacopa monnieri — Office for Science and Society, McGill University
Volver